Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

QIAGEN Welcomes WHO’s New Global Guidelines on Latent TB Screening

QIAGEN N.V.
Posted on: 22 Feb 18

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today endorsed new guidelines issued by the World Health Organization (WHO), which coordinates global efforts to control tuberculosis (TB), calling for harmonization of preventive screening and treatment of latent TB infection among vulnerable groups in countries with a high disease burden, as well as in low-burden countries. The guidelines also acknowledge the clinical value of modern blood tests for latent TB infection, including QIAGEN’s QuantiFERON-TB® Gold Plus.

Tuberculosis is a contagious bacterial infection spread primarily through coughing by patients with the active pulmonary form of the disease. In 2016, there were 10.4 million new cases of active TB worldwide and 1.7 million deaths from TB, according to WHO estimates. In latent tuberculosis infection (LTBI), the bacterium infects a person but produces no symptoms unless it progresses to active disease. As part of comprehensive programs to eradicate the disease, in recent years the WHO has continued to expand its guidelines for screening high-risk individuals and treating them for LTBI to prevent further contagion.

The new WHO guidelines Latent tuberculosis infection: Updated and consolidated guidelines for programmatic management expand the testing options, the number of groups for testing and treatment options. They remove the prior 2011 recommendation against the use of interferon gamma release assays (IGRAs) in low and middle income countries, where the burden of TB is highest. IGRAs or tuberculin skin test (TST) can now be used for LTBI testing globally. The new guidelines also acknowledge the higher benefit of preventive treatment among persons living with HIV testing positive and the global shortage of TST as a barrier to scaling up LTBI-prevention programs.

Please find the full press release here

To learn more about QFT-Plus, QFT and tuberculosis control, please visit www.quantiferon.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180222006185/en/

Business Wire
www.businesswire.com

Last updated on: 22/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.